| [PMID]: | 22836635 |
| [Au] Autor: | Mokra D; Drgova A; Kopincova J; Pullmann R; Calkovska A |
| [Ad] Dirección: | Department of Physiology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia. mokra@jfmed.uniba.sk |
| [Ti] Título: | Anti-inflammatory treatment in dysfunction of pulmonary surfactant in meconium-induced acute lung injury. |
| [So] Fuente: | Adv Exp Med Biol;756:189-96, 2013. |
| [Is] ISSN: | 0065-2598 |
| [Cp] País de publicación: | United States |
| [La] Idioma: | eng |
| [Ab] Resumen: | Inflammation, oxidation, lung edema, and other factors participate in surfactant dysfunction in meconium aspiration syndrome (MAS). Therefore, we hypothesized that anti-inflammatory treatment may reverse surfactant dysfunction in the MAS model. Oxygen-ventilated rabbits were given meconium intratracheally (25 mg/ml, 4 ml/kg; Mec) or saline (Sal). Thirty minutes later, meconium-instilled animals were treated by glucocorticoids budesonide (0.25 mg/kg, i.t.) and dexamethasone (0.5 mg/kg, i.v.), or phosphodiesterase inhibitors aminophylline (2 mg/kg, i.v.) and olprinone (0.2 mg/kg, i.v.), or the antioxidant N-acetylcysteine (10 mg/kg, i.v.). Healthy, non-ventilated animals served as controls (Con). At the end of experiments, left lung was lavaged and a differential leukocyte count in sediment was estimated. The supernatant of lavage fluid was adjusted to a concentration of 0.5 mg phospholipids/ml. Surfactant quality was evaluated by capillary surfactometer and expressed by initial pressure and the time of capillary patency. The right lung was used to determine lung edema by wet/dry (W/D) weight ratio. Total antioxidant status (TAS) in blood plasma was evaluated. W/D ratio increased and capillary patency time shortened significantly, whereas the initial pressure increased and TAS decreased insignificantly in Sal vs. Con groups. Meconium instillation potentiated edema formation and neutrophil influx into the lungs, reduced capillary patency and TAS, and decreased the surfactant quality compared with both Sal and Con groups (p > 0.05). Each of the anti-inflammatory agents reduced lung edema and neutrophil influx into the lung and partly reversed surfactant dysfunction in the MAS model, with a superior effect observed after glucocorticoids and the antioxidant N-acetylcysteine. |
| [Mh] Términos MeSH primario: |
Lesión Pulmonar Aguda/quimioterapia
Antiinflamatorios/uso terapéutico
Líquido del Lavado Bronquioalveolar/química
Líquido del Lavado Bronquioalveolar/citología
Síndrome de Aspiración de Meconio/quimioterapia
Síndrome de Aspiración de Meconio/fisiopatología
Surfactantes Pulmonares
|
| [Mh] Términos MeSH secundario: |
Acetilcisteína/uso terapéutico
Lesión Pulmonar Aguda/sangre
Lesión Pulmonar Aguda/etiología
Aminofilina/uso terapéutico
Animales
Antioxidantes/uso terapéutico
Budesonida/uso terapéutico
Dexametasona/uso terapéutico
Modelos Animales de Enfermedad
Humanos
Imidazoles/uso terapéutico
Recién Nacido
Recuento de Leucocitos
Pulmón/inmunología
Pulmón/fisiopatología
Meconio
Síndrome de Aspiración de Meconio/sangre
Neutrófilos/inmunología
Estrés Oxidativo
Inhibidores de Fosfodiesterasa/uso terapéutico
Edema Pulmonar
Piridonas/uso terapéutico
Conejos
|
| [Pt] Tipo de publicación: | JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T |
[Nm] Nombre de substancia:
| 0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Imidazoles); 0 (Phosphodiesterase Inhibitors); 0 (Pulmonary Surfactants); 0 (Pyridones); 317-34-0 (Aminophylline); 4Y8BMI9YGC (olprinone); 50-02-2 (Dexamethasone); 51333-22-3 (Budesonide); 616-91-1 (Acetylcysteine) |
| [Em] Mes de ingreso: | 1212 |
| [Sb] Subgrupo de revista: | IM |
| [Da] Fecha de ingreso para procesamiento: | 120727 |
| [St] Status: | MEDLINE |
| [do] DOI: | 10.1007/978-94-007-4549-0_24 |
